Prevalence and antimicrobial resistance patterns of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an istanbul university hospital

Chemotherapy

Volumn 55, Issue 4, 2009, Pages 293-297

  Koksal, Fatma ^a   Ak, Kenan ^a   Kucukbasmaci, Omer ^a   Samasti, Mustafa ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Escherichia coli; Extended spectrum lactamase; Klebsiella pneumoniae; Multidrug resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BLOOD CULTURE; DISK DIFFUSION; DRUG ISOLATION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; TURKEY;

EID: 66749135850     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224657     Document Type: Article

References (41)

1. Bradford PA: Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
2. Livermore DM: Beta-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998;41:25-41.
3. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-37.
4. Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
5. Warren RE, Harvey G, Carr R, Ward D, Doroshenko A: Control of infections due to extended-spectrum beta-lactamase-producing organisms in hospitals and the community. Clin Microbiol Infect 2008;14:124-133.
6. Moland ES, Kim SY, Hong SG, Thomson KS: Newer β-lactamases: clinical and laboratory implications, part II. Clin Microbiol Newsletter 2008;30:79-85.
7. Hawkey PM: Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008;14:159-165.
8. Bush K: Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008;14:134-143.
9. Goossens H, MYSTIC Study Group (Europe): MYSTIC programme: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001;41:183-189.
10. Leblebicioglu H, Gunaydin M, Esen S, Tuncer I, Findik D, Ural O, et al: Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Che-mother 2002;14:140-146.
11. Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M, et al: Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian J Med Microbiol 2007;25:346-350.
12. Korten V, Ulusoy S, Zarakolu P, Mete B: Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC program. Diagn Microbiol Infect Dis 2007;59:453-457.
13. Ozturk R, Koksal F, Ayar E, Koksal S, Basaran, Samasti M, et al: Antimicrobial susceptibility of enteric bacilli isolated from blood cultures (abstracts book 201/385). 10th Mediterranean Congr Chemother, Antalya, 2025 October, 1996.
14. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S18. Wayne, CLSI, 2008.
15. Jarlier V, Nicolas MH, Fournier G, Philippon A: Extended broad- spectrum beta-lactamase conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-878.
16. Vahaboglu H, Ozturk R, Aygun G, Coşkunkan F, Yaman A, Kaygusuz A, et al: Widespread detection of PER 1-type extendedspectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Che-mother 1997;41:2265-2269.
17. Winokur PL, Canton R, Caselass JM, Legakis N: Variations in the prevalence of strains expressing an extended spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32(suppl 2):94-103.
18. Cordero L, Rau R, Taylor D, Avers LW: Enteric Gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. Am J Infect Control 2004;32:189-195.
19. Cornaglia G, Garau J, Livermore DM: Living with ESBLs. Clin Microbiol Infect 2008;14:1-2.
20. Rossolini GM, D'Andrea MM, Mugnaioli C: The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008;14:33-41.
21. Rodríguez-Baño J, Navarro MD: Extendedspectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 2008;14:104-110.
22. Nicolas-Chanoine MH, Jarlier V: Extendedspectrum beta-lactamases in long-term care facilities. Clin Microbiol Infect 2008;14:111-116.
23. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al: Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008;14:144-153.
24. Livermore DM: Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 2008;14:3-10.
25. Livermore D, Canton R, Gniadkowski M, Nordmann P, Rossolini G, Arlet G, et al: CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-174.
26. Goossens H, Grabein B: Prevalence and antimicrobial susceptibility data for extendedspectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005;53:257-264.
27. Turner PJ: Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Micro-biol Infect Dis 2008;60:185-192.
28. Paterson DL: Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000;6:460-463.
29. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al: Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum flactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-478.
30. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS: Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002;52:99-106.
31. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO: Extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-1171.
32. Lautenbach E, Strom BL, Nachamkin I, Bilker WB, Marr AM, Larosa LA, et al: Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655-662.
33. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP: Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006;27:1226-1232.
34. Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, et al: Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002;8:473-478.
35. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al: Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species. Infect Control Hosp Epidemiol 2005;26:88-92.
36. Kocazeybek BS: Antimicrobial resistance surveillance of Gram-negative bacteria isolated from intensive care units of four different hospitals in Turkey. Evaluation of the prevalence of extended-spectrum and inducible beta-lactamases using different Etest strips and direct induction methods. Chemotherapy 2001;47:396-408.
37. Raveh D, Yinnon AM, Broide E, Rudensk B: Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Chemotherapy 2007;53:185-189.
38. Patzer JA, Dzierzanowska D, Turner PJ: Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother 2008;62:369-375.
39. Pfaller MA, Jones RN, Biedenbach DJ, Visalli M, Ravishankar J, Flores C, et al: Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001;41:177-182.
40. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, et al: Susceptibility to fluoro-quinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002;19:21-31.
41. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, et al: Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29:595-607